Physician profile
Stephen Bishop
NPI 1326045659
$2,193.50
in general payments reported to CMS, 2019-2025
17 companies · $851 in 2025
The $851 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.92 · 2020: $33.99 · 2021: $272 · 2022: $276 · 2023: $139 · 2024: $551 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,541.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $688.05 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $444.36 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Exact Sciences Corporation | $287.52 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $195.64 | 2020-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $95.91 | 2024-2025 | |
| Glaxosmithkline, LLC. | $82.63 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Axsome Therapeutics, INC. | $59.68 | 2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $57.17 | 2021 | |
| Abbvie INC. | $53.96 | 2022-2025 | |
| Amgen INC. | $46.97 | 2024 | Repatha, Otezla |
| Ultragenyx Pharmaceutical INC. | $43.61 | 2022-2024 | Crysvita |
| Aimmune Therapeutics, INC. | $37.12 | 2025 | Zenpep |
| Merck Sharp & Dohme LLC | $24.08 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $22.35 | 2024 | Veozah |
| Biohaven Pharmaceutical Holding Company Ltd. | $21.08 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.78 | 2025 | Xifaxan |
| Ironshore Pharmaceuticals INC. | $14.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.